A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm

Clinical trial NCT06597734 · WITHDRAWN

Trial details

NCT number: NCT06597734
Sponsor: M.D. Anderson Cancer Center
Status: WITHDRAWN
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Myelomonocytic Leukemia Advanced Myeloproliferative Neoplasms IDH1-mutated Higher-Risk Myelodysplastic Syndromes

Start date: 2025-01-28
Primary completion: 2026-06-11
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.